TP53 and atypical teratoid rhabdoid tumor: This could be in the upfront setting, when an effective standard of care (SOC) has not been developed, for tumours with an extremely short overall survival, such as paediatric-type diffuse high-grade glioma (PDHGG), in particular diffuse midline glioma (DMG); subtypes of medulloblastoma (especially Group 3/4 or SHH, TP53-altered), atypical teratoid/rhabdoid tumours (ATRT), embryonal tumours with multilayered rosettes (ETMR) and others.